PRESS RELEASE published on 05/19/2025 at 07:51, 1 year 2 months ago AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle AB Science reçoit un brevet chinois pour le masitinib dans le traitement du COVID-19 jusqu'en 2041, renforçant sa protection en propriété intellectuelle COVID-19 Propriété Intellectuelle AB Science Masitinib Brevet Chinois
PRESS RELEASE published on 05/19/2025 at 07:51, 1 year 2 months ago AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection AB Science receives Chinese patent protecting masitinib in the treatment of COVID-19 until 2041, providing long-term intellectual property protection. Collaboration with University of Chicago for COVID-19 research Intellectual Property COVID-19 Treatment AB Science Masitinib Chinese Patent
BRIEF published on 05/01/2025 at 10:11, 1 year 3 months ago AB Science reporte la publication de son rapport financier annuel 2024 Euronext Paris Rapport Financier Publication Retardée AB Science Masitinib
BRIEF published on 05/01/2025 at 10:11, 1 year 3 months ago AB Science postpones the publication of its 2024 annual financial report Euronext Paris Financial Report Publication Delayed AB Science Masitinib
PRESS RELEASE published on 05/01/2025 at 10:06, 1 year 3 months ago AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025 AB Science annonce le report de la publication de son rapport financier annuel 2024 au 9 mai 2025 pour achever l'audit. La société se spécialise dans les inhibiteurs de protéines kinases Rapport Financier Audit AB Science Masitinib Inhibiteurs De Protéines Kinases
PRESS RELEASE published on 05/01/2025 at 10:06, 1 year 3 months ago AB Science will publish its 2024 annual financial report on May 9, 2025 AB Science postpones the publication of its 2024 annual financial report to May 9, 2025, to allow auditors more time for audit work. The report will be released after trading hours Financial Report Postponement Auditors AB Science 2024 Annual Report
BRIEF published on 04/23/2025 at 19:04, 1 year 3 months ago EMA Grants Orphan Drug Status to AB8939 for AML Treatment AB Science AB8939 EMA Approval Acute Myeloid Leukemia Orphan Designation
BRIEF published on 04/23/2025 at 19:04, 1 year 3 months ago L'EMA accorde le statut de médicament orphelin à AB8939 pour le traitement de la LAM AB Science AB8939 Approbation De L'EMA Leucémie Myéloïde Aiguë Désignation D'orphelin
PRESS RELEASE published on 04/23/2025 at 18:59, 1 year 3 months ago AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia AB Science's AB8939 granted orphan drug designation by EMA in EU for treating acute myeloid leukemia, showing significant benefit over current therapies. Preclinical data reveals efficacy and safety Orphan Drug Designation AB Science EMA AB8939 Acute Myeloid Leukemia
PRESS RELEASE published on 04/23/2025 at 18:59, 1 year 3 months ago La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue La molécule AB8939 obtient la désignation de médicament orphelin dans l'Union Européenne pour le traitement de la leucémie myéloïde aigüe. AB Science fait un pas important dans le domaine de la recherche médicale Traitement AB Science Médicament Orphelin AB8939 Leucémie Myéloïde Aiguë
Published on 08/04/2026 at 17:00, 2 hours 9 minutes ago Moderna annonce le début d'un essai clinique de phase 1 portant sur l’ARNm-1469, son vaccin expérimental contre l'ébolavirus de Bundibugyo
Published on 08/04/2026 at 16:25, 2 hours 44 minutes ago ACCESS Newswire to Host Second Quarter Earnings Conference Call on August 11, 2026
Published on 08/04/2026 at 15:00, 4 hours 9 minutes ago Infield Minerals Expands Land Position at the Kings Canyon Gold Project in Utah
Published on 08/04/2026 at 15:00, 4 hours 9 minutes ago Secure Blockchain's Agentic Solutions Signs First Enterprise AI Customer
Published on 08/04/2026 at 14:30, 4 hours 39 minutes ago Agassi Sports Entertainment Launches Global "Let's Play" Pickleball and Padel Platform Initiative
Published on 08/04/2026 at 18:25, 44 minutes ago Amendment to the Prospectus of the Company and the Key Information Documents of the SubFunds
Published on 08/04/2026 at 18:00, 1 hour 9 minutes ago 2CRSi SA: Quanthor et 2CRSi s’associent pour sécuriser les infrastructures critiques à l’ère post-quantique
Published on 08/04/2026 at 18:00, 1 hour 9 minutes ago 2CRSi SA: Quanthor and 2CRSi join forces to secure critical infrastructure in the post-quantum era
Published on 08/04/2026 at 17:40, 1 hour 29 minutes ago Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.07.26
Published on 08/04/2026 at 18:32, 37 minutes ago Total number of voting rights and shares making up the share capital at July 31, 2026
Published on 08/04/2026 at 17:45, 1 hour 24 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 08/04/2026 at 17:45, 1 hour 24 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 08/04/2026 at 17:35, 1 hour 34 minutes ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote